Literature DB >> 1671578

Specific destruction of host-reactive mature T cells of donor origin prevents graft-versus-host disease in cyclophosphamide-induced tolerant mice.

M Eto1, H Mayumi, Y Tomita, Y Yoshikai, Y Nishimura, T Maeda, T Ando, K Nomoto.   

Abstract

In cyclophosphamide (CP)-induced tolerance, a long lasting skin allograft tolerance was established in many H-2-identical strain combinations without graft vs host disease. Destruction of donor-reactive T cells of host origin, followed by intrathymic clonal deletion of these cells, has been revealed to be the chief mechanisms of this system. Here, we studied the fate of host-reactive populations in donor-derived T cells of C3H/He (C3H) (H-2k, Mls-1b, Mls-2a) mice rendered CP-induced tolerant to AKR/J (AKR) (H-2k, Mls-1a, Mls-2b), by assessing AKR-derived Thy-1.1+ T cells bearing TCR V beta 3 that are specifically reactive with Mls-2a-encoded Ag of the recipient C3H mice. In the AKR-derived Thy-1.1+ lymph node cells of the C3H mice that had been treated with AKR spleen cells plus CP, CD4(+)-V beta 3+ T cells were obviously decreased by day 10 after the CP treatment. At this stage, the Thy-1.1+ T cells were not detected in the C3H thymus, suggesting that the obvious decrease of CD4(+)-V beta 3+ T cells of AKR origin was not due to intrathymic clonal deletion in the recipient C3H mice. Therefore, the destruction of the host-reactive mature T cells of donor origin, as well as that of the donor-reactive mature T cells of host origin, occurred by the CP treatment at the induction phase. Furthermore, after the establishment of intrathymic mixed chimerism in the recipient C3H mice, V beta 3+ T cells were not detected among the Thy-1.1+ T cells of AKR origin in the mixed chimeric thymus, suggesting that the host-reactive immature T cells repopulated from the injected donor hematopoietic cells were clonally deleted in the recipient thymus. These two mechanisms appear to prevent graft vs host disease in CP-induced tolerance.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1671578

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  31 in total

1.  Importance of intrathymic mixed chimerism for the maintenance of skin allograft tolerance across fully allogeneic antigens in mice.

Authors:  M Eto; Y Y Kong; J Uozumi; S Naito; K Nomoto
Journal:  Immunology       Date:  1999-03       Impact factor: 7.397

2.  Sequential therapy combining clofarabine and T-cell-replete HLA-haploidentical haematopoietic SCT is feasible and shows efficacy in the treatment of refractory or relapsed aggressive lymphoma.

Authors:  A-K Zoellner; S Fritsch; D Prevalsek; N Engel; M Hubmann; R Reibke; C T Rieger; J C Hellmuth; M Haas; F Mumm; T Herold; G Ledderose; W Hiddemann; M Dreyling; A Hausmann; J Tischer
Journal:  Bone Marrow Transplant       Date:  2015-02-02       Impact factor: 5.483

Review 3.  HLA-haploidentical blood or marrow transplantation with high-dose, post-transplantation cyclophosphamide.

Authors:  E J Fuchs
Journal:  Bone Marrow Transplant       Date:  2015-06       Impact factor: 5.483

Review 4.  Nonmyeloablative allogeneic hematopoietic cell transplantation.

Authors:  Rainer Storb; Brenda M Sandmaier
Journal:  Haematologica       Date:  2016-05       Impact factor: 9.941

5.  Impact of high-dose steroid premedication on the outcome of myeloablative T-cell replete haploidentical peripheral blood stem cell transplant.

Authors:  Ayman Saad; Alankrita Taneja; Antonio Di Stasi; Rehan Sarmad; Rivvi Kukkamalla; Luciano Costa; Donna Salzman; Racquel Innis-Shelton; Joseph H Chewning; Ruby F Meredith; Vera Hauptfeld; Samantha Langford; KirbyAnn Plessala; Ravi Bhatia; Lawrence S Lamb; Shin Mineishi
Journal:  Bone Marrow Transplant       Date:  2018-05-04       Impact factor: 5.483

6.  Prevention and reversal of adoptively transferred, chronic relapsing experimental autoimmune encephalomyelitis with a single high dose cytoreductive treatment followed by syngeneic bone marrow transplantation.

Authors:  D M Karussis; U Vourka-Karussis; D Lehmann; H Ovadia; R Mizrachi-Koll; A Ben-Nun; O Abramsky; S Slavin
Journal:  J Clin Invest       Date:  1993-08       Impact factor: 14.808

7.  Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome.

Authors:  Yvette L Kasamon; Leo Luznik; Mary S Leffell; Jeanne Kowalski; Hua-Ling Tsai; Javier Bolaños-Meade; Lawrence E Morris; Pamela A Crilley; Paul V O'Donnell; Nancy Rossiter; Carol Ann Huff; Robert A Brodsky; William H Matsui; Lode J Swinnen; Ivan Borrello; Jonathan D Powell; Richard F Ambinder; Richard J Jones; Ephraim J Fuchs
Journal:  Biol Blood Marrow Transplant       Date:  2010-01-18       Impact factor: 5.742

Review 8.  Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantation.

Authors:  Leo Luznik; Paul V O'Donnell; Ephraim J Fuchs
Journal:  Semin Oncol       Date:  2012-12       Impact factor: 4.929

9.  Haploidentical Related Donor Hematopoietic Stem Cell Transplantation for Dedicator-of-Cytokinesis 8 Deficiency Using Post-Transplantation Cyclophosphamide.

Authors:  Nirali N Shah; Alexandra F Freeman; Helen Su; Kristen Cole; Mark Parta; Niki M Moutsopoulos; Safa Baris; Elif Karakoc-Aydiner; Thomas E Hughes; Heidi H Kong; Steve M Holland; Dennis D Hickstein
Journal:  Biol Blood Marrow Transplant       Date:  2017-03-10       Impact factor: 5.742

10.  Preclinical models of acute and chronic graft-versus-host disease: how predictive are they for a successful clinical translation?

Authors:  Robert Zeiser; Bruce R Blazar
Journal:  Blood       Date:  2016-03-18       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.